Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2020
Accounting Basis: International Financial Reporting Standards (IFRS)
Currency: Danish Kroner (DKK)
Novo Nordisk is a global healthcare company and a world leader in diabetes care, with additional leading positions in hemophilia and growth hormone therapy. The company operates two business segments: Diabetes and Obesity care (comprising over 84% of sales) and Biopharm. The company employs approximately 45,000 people in 80 countries and markets products in approximately 170 countries.
Key Financial Metrics
Note: Specific consolidated revenue, net profit, and cash flow figures for 2020 are not explicitly stated in the provided text, which incorporates the Annual Report by reference. The following data points are available from the filing text:
- Dividends: Total dividend for 2020 was DKK 9.10 per share (DKK 5.85 proposed final + DKK 3.25 interim), translating to approximately $1.50 per share/ADR.
- Capital Stock: DKK 470 million (2020) vs. DKK 480 million (2019).
- Treasury Stock: DKK (8) million (2020) vs. DKK (10) million (2019).
- Share Repurchases:
- 2019 Program (completed Feb 2020): 43,209,505 shares purchased at an average price of DKK 347.15.
- 2020 Program (initiated Feb 2020): 37,600,522 shares purchased at an average price of DKK 424.85. Remaining value under this program was approx. DKK 1.0 billion as of Dec 31, 2020.
- Key Product Sales (2020):
- NovoLog/NovoRapid: DKK 16,928 million.
- NovoLog Mix/NovoMix: DKK 9,634 million.
- Victoza: DKK 18,747 million.
- Saxenda: DKK 5,608 million.
- Ozempic: DKK 21.2 billion.
- Research & Development (R&D): Expected to remain around 12-13% of sales. R&D organization comprised approx. 8,000 employees.
Material Changes and Operational Highlights
- Product Launches and Approvals: Rybelsus (oral GLP-1) was launched broadly in the U.S. in 2020 and approved in Europe and Japan. Tresiba was added to China's National Reimbursement Drug List effective Jan 2020.
- Patent Expirations: Compound patents for NovoLog/NovoRapid and NovoLog Mix/NovoMix expired in all markets. Victoza and Saxenda patents expire in 2023 in the U.S. and Europe, though generic entry is delayed until 2024 due to settlements.
- Market Dynamics: In the U.S., average prices after rebates declined in 2020 due to payer pressure and legislative changes to Medicare Part D. Ozempic achieved a 34% New-to-Brand Prescriptions (NBRx) market share in the U.S.
- Capital Expenditures: Significant investments included DKK 850 million for Kalundborg, Denmark expansion; EUR 81 million for Chartres, France; and USD 70 million for a tablet facility in Durham, North Carolina.
Outlook, Risks, and Management Commentary
Guidance and Outlook
Management expects average prices after rebates in the U.S. to decline further in 2021, predominantly driven by the insulin class. However, market access is expected to remain similar to 2020 levels. The company anticipates R&D spending to follow a trend in line with or slightly above sales growth.
Risk Factors
- COVID-19 Pandemic: Risks include reduced patient visits, supply chain disruptions, and potential production suspensions. The magnitude of impact remains uncertain.
- Brexit: Uncertainty remains regarding supply chain management, pharmaceutical regulations, and licensing requirements following the UK's exit from the EU. The company has incurred costs building stock in UK warehouses.
- Cybersecurity: Reliance on IT systems creates risks of service interruptions or data breaches, which could negatively impact operations and reputation.
- Iran Transactions: The company conducts limited business in Iran (gross revenue <1% of Group sales) involving distribution, educational programs, and a new manufacturing facility. Receivables from Iranian entities remain outstanding with uncertain payment timelines.
Unusual Items
The filing notes that the provision for sales rebates and discounts in the U.S. business amounted to DKK 34,052 million as of December 31, 2020, representing a critical audit matter due to the significant judgment required in estimating these obligations.
Investor Verification Checklist
- Verify the full consolidated revenue, net profit, and free cash flow figures in the referenced Annual Report 2020 (pages 47-77), as specific totals are not in this text.
- Monitor the timeline for generic entry of Victoza and Saxenda, specifically the June 2024 expected launch date for Teva's generic version of Victoza in the U.S.
- Assess the impact of continued U.S. price pressure and rebate increases on net realized prices in 2021.
- Review the status of the Mutual Recognition Agreement (MRA) on medicines between the UK and EU to evaluate ongoing Brexit-related supply chain risks.
- Confirm the progress of the new manufacturing facility in Iran and the collectability of outstanding receivables from Iranian government-controlled entities.
- Track the regulatory approval status of pipeline compounds, specifically oral semaglutide and once-weekly insulin icodec.